EU/3/19/2205

Table of contents

About

On 17 October 2019, orphan designation EU/3/19/2205 was granted by the European Commission to Quality Regulatory Clinical Ireland Limited, Ireland, for 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide-methane sulfonic acid salt (also known as KD025) for the treatment of graft-versus-host disease.

Key facts

Active substance
2-(3-(4-(1H-Indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide-methane sulfonic acid salt
Disease / condition
Treatment of graft-versus-host disease
Date of first decision
17/10/2019
Outcome
Positive
EU designation number
EU/3/19/2205

Sponsor's contact details

Quality Regulatory Clinical Ireland Limited
Priory Office Park 21
Stillorgan
Co Dublin
A94 F660
Ireland
Tel. +353 1210 0440
E-mail: sarah.nicholson@qrcc.co.uk

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating